Biogen's Strategic Acquisitions and Growth Potential: An Analyst's Hold Rating Justification
Goldman Sachs Adjusts Price Target on Biogen to $342 From $340, Maintains Buy Rating
Biogen Analyst Ratings
Piper Sandler Adjusts Biogen's Price Target to $313 From $335, Keeps Overweight Rating
Morgan Stanley Adjusts Price Target on Biogen to $311 From $331
Barclays Remains a Hold on Biogen (BIIB)
RBC Cuts Price Target on Biogen to $303 From $317, Keeps Outperform Rating
Biogen Analyst Ratings
Wedbush Adjusts Price Target on Biogen to $215 From $219
Biogen Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Gilead Sciences (GILD), Biogen (BIIB) and Argenx Se (ARGX)
Biogen Analyst Ratings
RBC Capital Sticks to Its Buy Rating for Biogen (BIIB)
Analysts Offer Insights on Healthcare Companies: Inari Medical (NARI), Biogen (BIIB) and SOPHiA GENETICS (SOPH)
Biogen's Strategic Diversification and Financial Strategy Garner Outperform Rating
Strategic Acquisitions and Clinical Catalysts Bolster Biogen's Buy Rating
Biogen (BIIB) Gets a Buy From Oppenheimer
Analysts' Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB) and Incyte (INCY)
Biogen Analyst Ratings
Wedbush Raises Biogen Price Target to $219 From $215, Maintains Neutral Rating